bremelanotide   Click here for help

GtoPdb Ligand ID: 10408

Synonyms: PT-141 | PT141 | Vyleesi®
Approved drug
bremelanotide is an approved drug (FDA (2019))
Comment: Bremelanotide is a stabilised, cyclic derivative of αMSH. Although it exhibits little selectivity across the melanocortin receptor family (with the exception of MC2, the ACTH receptor), bremelanotide's ability to increase female sexual arousal/desire is attributed primarily to agonist activity at the MC3 and MC4 receptors [2].
HELM annotation is PEPTIDE1{[ac].[Nle].D.H.[dF].R.W.K}$PEPTIDE1,PEPTIDE1,3:R3-8:R3$$$.
Click here for help
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)Cc1[nH]cnc1)Cc1ccccc1)CCCN=C(N)N)Cc1c[nH]c2c1cccc2)C(=O)O)NC(=O)C
Isomeric SMILES CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)Cc1[nH]cnc1)Cc1ccccc1)CCCN=C(N)N)Cc1c[nH]c2c1cccc2)C(=O)O)NC(=O)C
InChI InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
InChI Key FFHBJDQSGDNCIV-MFVUMRCOSA-N
No information available.
Summary of Clinical Use Click here for help
A subcutaneous injectible form of bremelanotide is approved as a treatment for premenopausal women suffering from hypoactive sexual desire disorder (HSDD).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Agonist activity at the MC3 and MC4 receptors is thought to underlie bremelanotide's downstream CNS effects of increasing arousal and desire [2].